ITM 2.0: Advancing Translational Science in Metropolitan Chicago

摘要 ITM 2.0：推进芝加哥大都会的翻译科学 芝加哥大学(UChicago)转化医学研究所(ITM)成立于2007年，旨在 整合、整合和创造催化所需的智力、管理和物质资源 临床和转化科学的研究和研究培训。我们培养了大学科学家和 卫生保健提供者与所有相关社区的利益攸关方合作，以确定 疾病的分子、遗传、病理生理和社会决定因素；开发和测试干预措施 以这些机制为导向；并以严格、高效、道德、 尊重并响应我们社区的需求和价值观。在最初的9年里，ITM已经将 关于整个芝加哥大学和ITM附属机构-Rush的杰出智力和物质资源 大学医学中心(Rush)、北岸大学医疗系统(NorthShore)和伊利诺伊学院 技术(IIT)-为实现变革性、能源化和自我完善的家庭构建基础设施 临床和转化性研究。现在，我们为ITM 2.0追求一个大胆的指导性愿景--健康结果 将通过以下方式降低疾病风险、发病率和死亡率，从而改善整个芝加哥 协作、多学科的团队科学。我们将通过汇集科学的、 机构和社区利益相关者，共同关注最高价值主张以改进 相互定义的健康问题，利用协同效应加快翻译工作的进展 频谱。我们的核心信念是，参与健康研究是共同的自我利益和 社会公正，这是我们在未来20年将共同努力的一种“新常态”的主流观点。 ITM 2.0将与芝加哥和全国各地的卫生利益相关者携手合作， 构思、开发和部署创新的进程和做法，以实现我们的共同目标。 为迎接这一雄心勃勃的挑战，我们扩大了机构和社区利益攸关方的范围。 拉什现在加入芝加哥大学，担任ITM牵头机构和洛约拉大学医学中心和倡导者 Healthcare加入为ITM附属公司。我们与受人尊敬的机构合作-芝加哥社区信托， 伊利诺伊州生物技术产业组织以及芝加哥和伊利诺伊州公共卫生部--以及 充分利用与另外两个芝加哥CTSA的密切合作，以及全芝加哥的PCORnet CDRN摩羯座，并与最近授予伊利诺伊州精准医学联盟。在ITM 2.0中，我们将 共同开发创新的方法，有时甚至是颠覆性的方法，以推动 临床和转化性研究，严格确定哪些方法有效，然后传播 成功和失败的结果。我们预计，这一方法将改善和改善 临床和转化性研究培训，造福于芝加哥、CTSA联盟和国家。

ABSTRACT ITM 2.0: ADVANCING TRANSLATIONAL SCIENCE IN METROPOLITAN CHICAGO The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.